Fix Brian V, Adkison Sarah E, O'Connor Richard J, Bansal-Travers Maansi, Cummings K Michael, Rees Vaughan W, Hatsukami Dorothy K
Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY, USA.
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
Health Educ J. 2017 Dec;76(8):971-985. doi: 10.1177/0017896917729723. Epub 2017 Sep 20.
The US Food and Drug Administration (FDA) has regulatory authority for modified risk tobacco product advertising claims. To guide future regulatory efforts, we investigated how variations in modified risk claim advertisements influence consumer perceptions of product risk claims for Camel Snus.
Young people and adults (15-65), including current, never, and former smokers, were randomised to view one of five Camel Snus print advertisements as part of a web-based survey. Four of the advertisements presented information related to nitrosamine content of snus using four formats: (1) text, (2) a bar chart, (3) a text/testimonial and (4) a bar chart/testimonial. The fifth format, used as a control, was a current advertisement for Camel Snus without the explicit claims made about nitrosamine content. After viewing advertisements for all products, participants were asked which product they would be most interested in trying.
Participants exposed to advertisements that contained an explicit reduced risk message agreed the advertising claim for that product posed fewer health risks than cigarettes. However, advertisements containing the reduced risk messages were also viewed as containing less truthful information and respondents were more sceptical of the information presented. Advertisement claim format was not associated with selecting snus over the other tobacco products, nor was it associated with purchase intentions.
The results of this research indicate that consumers respond to reduced risk messages, though perhaps not in the direct way anticipated. We found no significant differences by advertisement format (numerical, graphical, testimonial).
美国食品药品监督管理局(FDA)对改良风险烟草产品的广告声明拥有监管权。为指导未来的监管工作,我们调查了改良风险声明广告的变化如何影响消费者对骆驼鼻烟产品风险声明的认知。
年轻人和成年人(15 - 65岁),包括当前吸烟者、从不吸烟者和曾经吸烟者,被随机分配观看五个骆驼鼻烟平面广告中的一个,作为基于网络的调查的一部分。其中四个广告使用四种形式呈现与鼻烟亚硝胺含量相关的信息:(1)文字,(2)柱状图,(3)文字/推荐语,(4)柱状图/推荐语。第五种形式用作对照,是骆驼鼻烟的当前广告,没有关于亚硝胺含量的明确声明。在观看所有产品的广告后,参与者被问及他们最感兴趣尝试的产品是哪一个。
接触到包含明确降低风险信息广告的参与者认同该产品的广告声明所带来的健康风险比香烟少。然而,包含降低风险信息的广告也被认为包含的真实信息较少,并且受访者对所呈现的信息更持怀疑态度。广告声明形式与选择鼻烟而非其他烟草产品无关,也与购买意愿无关。
这项研究的结果表明,消费者对降低风险信息有反应,尽管可能并非以预期的直接方式。我们发现广告形式(数字、图形、推荐语)没有显著差异。